Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | USP19 | O94966 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29333811 | 1.00 | CCNC (0.36) | CCNCCDK8PIK3CAMAPK1ALOX5AP | |
| SCHEMBL29333821 | 0.93 | CCNC (0.36) | CCNCCDK8PIK3CAMAPK1ALOX5AP | |
| SCHEMBL30855231 | 0.93 | CCNC (0.36) | CCNCCDK8PIK3CAMAPK1ALOX5AP | |
| SCHEMBL29333817 | 0.89 | CCNC (0.34) | CCNCCDK8PIK3CAMAPK1BTK | |
| SCHEMBL30855042 | 0.89 | CCNC (0.34) | CCNCCDK8PIK3CAMAPK1BTK | |
| SCHEMBL31008576 | 0.87 | CCNC (0.34) | CCNCCDK8PIK3CAMAPK1BTK | |
| SCHEMBL29333450 | 0.87 | CCNC (0.34) | CCNCCDK8PIK3CAMAPK1BTK | |
| SCHEMBL29335758 | 0.87 | CCNC (0.34) | CCNCCDK8PIK3CAMAPK1BTK | |
| SCHEMBL31223579 | 0.84 | MAPK1 (0.35) | CCNCCDK8PIK3CAMAPK1ALOX5AP | |
| SCHEMBL31223539 | 0.84 | MAPK1 (0.35) | CCNCCDK8PIK3CAMAPK1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594308-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | Vividion Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024073587-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | CCNC 4349/4885CDK8 1776/4885PIK3CA 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.